George Adam D. 4

Accession 0000899243-21-002235

CIK 0001351288other

View on SEC.gov Company Profile

Filed

Jan 14, 7:00 PM ET

Accepted

Jan 15, 8:00 PM ET

Size

62.0 KB

Accession

0000899243-21-002235

Insider Transaction Report

Form 4

Period: 2021-01-13

GW PHARMACEUTICALS PLCGWPH

George Adam D.

Secretary

Transactions

Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+5,868$8→ 512,320 total
Exercise/Conversion
Share Options
2021-01-13−97,008→ 10 total
Exercise: $0.00Exp: 2026-02-15→ Ordinary Shares (97,008 underlying)
Exercise/Conversion
Share Options
2021-01-13−99,180→ 0 total
Exercise: $0.00Exp: 2027-01-06→ Ordinary Shares (99,180 underlying)
Exercise/Conversion
Share Options
2021-01-13−78,336→ 0 total
Exercise: $0.00From: 2020-12-31Exp: 2029-03-01→ Ordinary Shares (78,336 underlying)
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+132,984$186→ 410,512 total
Sale
Ordinary Shares
2021-01-13$11.15/sh−121,764$1,357,669→ 14,740 total
Sale
Ordinary Shares
2021-01-13$11.23/sh−4,740$53,230→ 10,000 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+97,008$136→ 110,644 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+99,180$139→ 277,528 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+78,336$110→ 488,848 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+5,868$8→ 494,716 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+77,088$108→ 685,744 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+3,636$5→ 13,636 total
Exercise/Conversion
Ordinary Shares
2021-01-13$3.72/sh+67,704$251,859→ 178,348 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+5,868$8→ 500,584 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+5,868$8→ 506,452 total
Exercise/Conversion
Ordinary Shares
2021-01-13$0.00/sh+96,336$135→ 608,656 total
Sale
Ordinary Shares
2021-01-13$10.91/sh−181,488$1,980,034→ 504,256 total
Sale
Ordinary Shares
2021-01-13$11.00/sh−145,200$1,597,200→ 359,056 total
Sale
Ordinary Shares
2021-01-13$11.08/sh−222,552$2,465,876→ 136,504 total
Exercise/Conversion
Share Options
2021-01-13−3,636→ 0 total
Exercise: $0.00From: 2019-06-24Exp: 2025-06-24→ Ordinary Shares (3,636 underlying)
Exercise/Conversion
Share Options
2021-01-13−67,704→ 3 total
Exercise: $3.72From: 2019-02-15Exp: 2026-02-15→ Ordinary Shares (67,704 underlying)
Exercise/Conversion
Share Options
2021-01-13−132,984→ 0 total
Exercise: $0.00Exp: 2028-02-26→ Ordinary Shares (132,984 underlying)
Exercise/Conversion
Share Options
2021-01-13−5,868→ 0 total
Exercise: $0.00From: 2020-12-31Exp: 2029-03-01→ Ordinary Shares (5,868 underlying)
Exercise/Conversion
Share Options
2021-01-13−5,868→ 0 total
Exercise: $0.00From: 2020-12-31Exp: 2029-03-01→ Ordinary Shares (5,868 underlying)
Exercise/Conversion
Share Options
2021-01-13−77,088→ 0 total
Exercise: $0.00From: 2020-12-31Exp: 2030-06-04→ Ordinary Shares (77,088 underlying)
Exercise/Conversion
Share Options
2021-01-13−5,868→ 0 total
Exercise: $0.00From: 2020-03-01Exp: 2029-03-01→ Ordinary Shares (5,868 underlying)
Exercise/Conversion
Share Options
2021-01-13−5,868→ 0 total
Exercise: $0.00From: 2020-12-31Exp: 2029-03-01→ Ordinary Shares (5,868 underlying)
Exercise/Conversion
Share Options
2021-01-13−96,336→ 32,112 total
Exercise: $0.00From: 2020-12-31Exp: 2030-06-04→ Ordinary Shares (96,336 underlying)

Footnotes (13)

[F1]Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares of ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
[F10]9,624 shares vested on February 15, 2020. The remaining vested on February 15, 2019.
[F11]6,468 shares vested on December 31, 2020 (accelerated due to retirement of the reporting person.) The remaining vested on January 6, 2020.
[F12]7,680 shares vested on February 26, 2019; 7,668 shares vested on February 26, 2020; the remained vested on December 31, 2020 (accelerated due to retirement of the reporting person.)
[F13]Accelerated due to retirement of the reporting person.
[F2]Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.36 U.S. Dollars as of January 13, 2020.
[F3]The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
[F4]Represented by ADSs.
[F5]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($130.9153 per ADS). These shares were sold in multiple transactions at prices ranging from $130.48 per ADS (or $10.87 per ordinary share) to $131.44 per ADS (or $10.95 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F6]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($132.0454 per ADS). These shares were sold in multiple transactions at prices ranging from $130.48 per ADS (or $10.87 per ordinary share) to $132.48 per ADS (or $11.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F7]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($132.9121 per ADS). These shares were sold in multiple transactions at prices ranging from $132.50 per ADS (or $11.04 per ordinary share) to $133.48 per ADS (or $11.12 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F8]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($133.7875 per ADS). These shares were sold in multiple transactions at prices ranging from $133.50 per ADS (or $11.13 per ordinary share) to $134.48 per ADS (or $11.21 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F9]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($134.7871 per ADS). These shares were sold in multiple transactions at prices ranging from $134.54 per ADS (or $11.21 per ordinary share) to $134.97 per ADS (or $11.25 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

GW PHARMACEUTICALS PLC

CIK 0001351288

→

Entity typeother

Related Parties

filerCIK 0001754239

Filing Metadata

Form type: 4
Filed: Jan 14, 7:00 PM ET
Accepted: Jan 15, 8:00 PM ET
Size: 62.0 KB

View on SEC.gov